Study Assessing High-Frequency Chest Wall Oscillation (HFCWO) in Preventing Pulmonary Exacerbations
Completed · Not applicable
Conditions studied: Cerebral Palsy
In brief
To asssess efficacy of airway clearance provided by Vest therapy (HFCWO) in the reduction of respiratory exacerbations requiring hospitalization or antibiotic utilization in patients with muscle weakness and restrictive lung disease.
Key facts
- Study ID
- NCT00739310
- Run by
- Hill-Rom
- People needed
- 29
- Starts
- 2008-08-01
- Expected to finish
- 2011-07-01
- Last updated by the study team
- 2017-08-07
Who can join
Age: 2 and older, up to 18. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Subject is at least 18 months old.
- Subject has a chest circumference of greater than 19 inches.
- Subject has a diagnosis of muscle weakness and restrictive lung disease.
- Ability to provide Informed consent from legal guardian.
- Subject has had 2 or more exacerbations requiring either hospitalization or antibiotics (IV or oral) in the past 12 months
- If inhaled Tobramycin has been prescribed prophylacticly, subjects must discontinue the medication at least 2 weeks prior to study enrollment
You may not qualify if…
- Subject has a diagnosed allergy with a respiratory trigger.
- Participation in another clinical trial.
- Unstable head or spinal injury.
- Unresolved pneumothorax or pneumomediastinum present
- Unresolved hemorrhage
- Hypotension requiring vasopressors or positioning
- Bronchopleural fistula
- Gross hemoptysis within the past eight hours
- Pulmonary embolism or history of pulmonary embolism within the past two months
- Burns, open wounds and skin infections on the thorax
- Osteomyelitis of the ribs
- Osteoporosis with history of fractures.
Where it is running
- Maimonides Medical Center — Brooklyn, New York, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.